Portfolio manager

Richard Sadowsky Appointed as Interim CEO; Kurt Lageschulte Returns to the Board of Directors

Retrieved on: 
Thursday, March 14, 2024
Advisory board, Recycling, ID4, History, Portfolio manager, Interim, OTCQB, Broadbill

Mr. Sadowsky is a New York-based lawyer and business consultant with four decades of experience in complex transactions and investment banking.

Key Points: 
  • Mr. Sadowsky is a New York-based lawyer and business consultant with four decades of experience in complex transactions and investment banking.
  • The Company is also pleased to announce the return of Kurt Lageschulte to RecycLiCo’s Board of Directors.
  • He served on the RecycLiCo Board from 2012 - 2021 and has been serving on its Advisory Board since that time.
  • Kurt Lageschulte is someone I know to be a creative and effective investor and fund raiser and all of us on the Board are excited at his return.”

AlbaCore Expands Investment Team with Two Senior Hires

Retrieved on: 
Wednesday, March 27, 2024
Finance, Business, Banking, Professional Services, Asset Management, Growth, Philosophy, Albacore, Bank, Research, Lisp (programming language), Société Générale, Senior, Morgan Stanley, Portfolio manager, BofA Securities, CQS, Management

European credit specialist, AlbaCore Capital Group (“AlbaCore”), is pleased to announce the appointment of Davide Chiesa as the firm’s Head of Research, and Sheharyar Malik as a Director in the Investment Team.

Key Points: 
  • European credit specialist, AlbaCore Capital Group (“AlbaCore”), is pleased to announce the appointment of Davide Chiesa as the firm’s Head of Research, and Sheharyar Malik as a Director in the Investment Team.
  • In a newly created role on the investment team, Davide will be responsible for leading AlbaCore’s expanding research function, helping to inform the firm’s investment processes.
  • Davide will lead a team of analysts who supports AlbaCore’s offering across private and opportunistic credit strategies as well as CLOs and structured credit.
  • They both bring extensive experience in European credit to their roles, helping bolster the senior ranks of the firm,” said Matthew Courey, President and COO, AlbaCore.

Eagle Capital Launches Eagle Capital Select Equity ETF (EAGL)

Retrieved on: 
Monday, March 25, 2024
Asset Management, Professional Services, Finance, CIO, Growth, Goldman Sachs, ETF, Philosophy, Partnership, EAGL, Portfolio manager

Eagle Capital Management (Eagle) , an independent asset manager based in New York City, today launched its first exchange-traded fund, the Eagle Capital Select Equity ETF (NYSE Arca: EAGL).

Key Points: 
  • Eagle Capital Management (Eagle) , an independent asset manager based in New York City, today launched its first exchange-traded fund, the Eagle Capital Select Equity ETF (NYSE Arca: EAGL).
  • Eagle, founded in 1988, manages a public equity strategy with assets under management of more than $26 billion.
  • The new EAGL ETF relies on the same focused investment philosophy Eagle has deployed since its inception.
  • “Our North Star is buying undervalued companies with unrecognized long-term growth potential, and our aim is to protect, preserve, and grow our clients’ capital.

Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors

Retrieved on: 
Tuesday, March 12, 2024
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, Pulmonary hypertension, Health care, Artificial intelligence, American Thoracic Society, Whitehead Institute, Lung transplantation, Idiopathic pulmonary fibrosis, Medical director, Biomedical Research, Pulmonology, Capital Group Companies, Gossamer, Partnership, American College, Wellesley College, American studies, Commerce, Creative, Medical education, Biomedicine, Latin American studies, International Society, Putnam Investments, MNTN, University, Senior, House, Publication, Portfolio manager, FDA, Internal medicine, Entrepreneurship, Lord Abbett, MIT, Capital, Bloomberg, GOSS, Orthostatic hypertension, IPF, Initial public offering, Partner, Idiopathic disease, PAH, Pharmaceutical industry

Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.

Key Points: 
  • Skye Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., and a former Partner and Senior BioPharma Analyst at Capital Group.
  • Ms. Drynan joins the Board with an extensive background in finance, investment, and entrepreneurship, specializing in the biotechnology industry.
  • “The addition of Dr. Nathan to our Board signifies a pivotal moment in Gossamer’s evolution,” said Faheem Hasnain, Co-Founder, Chairman and CEO of Gossamer Bio.
  • Ms. Drynan is the Founder, CEO and Creative Director of House of Skye, Ltd., which she founded in 2016.

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

Retrieved on: 
Tuesday, February 27, 2024
BRAF, Therapy, SAN, Eventide, Research, AML, GSK, PARP, Cancer, Platinum, Portfolio manager, Drug development, Uterine serous carcinoma, Medication, Webcast, Ovarian cancer, Administration, PROC, USC, Patient, Pharming, MPH, Link, Development, NDA, WEE1, Acute myeloid leukemia, Partnership, Pharmaceutical industry

NEW YORK and SAN DIEGO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced financial results for the year ended December 31, 2023, and highlighted recent corporate accomplishments.

Key Points: 
  • "Zentalis is making remarkable progress in advancing our clinical development program for azenosertib, our potentially groundbreaking WEE1 inhibitor, across various tumor types," stated Kimberly Blackwell, M.D., Chief Executive Officer of Zentalis.
  • "In November 2023, we disclosed promising clinical data demonstrating the potential of azenosertib as an effective monotherapy in ovarian cancer and uterine serous carcinoma.
  • On November 10, 2023, Zentalis participated in a webcast with Joyce F. Liu, M.D., MPH, to discuss azenosertib ovarian cancer clinical data.
  • General and Administrative Expenses: General and administrative expenses for the year ended December 31, 2023 were $64.4 million, compared to $54.6 million during the year ended December 31, 2022.

Sensata Technologies Appoints John Mirshekari to Its Board of Directors

Retrieved on: 
Tuesday, February 20, 2024
Electronic Design Automation, Engineering, Technology, Aerospace, Manufacturing, Software, Machinery, Fidelity, Multimedia, Investment, Fidelity Investments, Portfolio manager, Growth, Committee on Finance, Equity, Partners Capital

Sensata Technologies Holding plc (NYSE: ST) today announced that John Mirshekari has been appointed to Sensata’s Board of Directors and to serve on the Growth & Innovation Committee and the Finance Committee, effective March 1, 2024.

Key Points: 
  • Sensata Technologies Holding plc (NYSE: ST) today announced that John Mirshekari has been appointed to Sensata’s Board of Directors and to serve on the Growth & Innovation Committee and the Finance Committee, effective March 1, 2024.
  • View the full release here: https://www.businesswire.com/news/home/20240220998110/en/
    Mr. Mirshekari brings more than two decades of finance, investment and strategic execution experience to Sensata’s Board of Directors.
  • “John brings decades of experience in business strategy, shareholder value creation and corporate governance, as well as an institutional investor,” said Andrew Teich, Chairman of the Board of Sensata.
  • On behalf of our Board, we welcome John, and I am confident that he will be a great addition to the Sensata team.”

LifeVantage Appoints Dayton Judd to the Board of Directors

Retrieved on: 
Thursday, February 15, 2024
Protandim, Certified Public Accountant, Dayton, Ohio, Brigham Young University, Portfolio manager, McKinsey & Company, Growth, Audit committee, Health, Harvard Business School, Management

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Dayton Judd to the Company’s Board of Directors (the “Board”), effective immediately, in an expansion of the Board.

Key Points: 
  • SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN) a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced the appointment of Dayton Judd to the Company’s Board of Directors (the “Board”), effective immediately, in an expansion of the Board.
  • During these discussions, the Company and the Radoff-Sudbury Group worked together to create a framework for long-term collaboration between the parties.
  • The appointment of Dayton Judd to the Board is in connection with a Cooperation Agreement entered into between the Company and the Radoff-Sudbury Group.
  • Steve Fife, LifeVantage’s President and Chief Executive Officer, commented, “We welcome Dayton to the Board and believe his insights and perspective will benefit the Company and its shareholders.

Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments

Retrieved on: 
Thursday, January 25, 2024
Citadel, Portfolio manager, Neoplasm, Pharming, T. Rowe Price, Biology, Research, Health care, SAN, Medical school, Science, Princeton University, University, Pharmacology, Denison University, Cancer, Medication, Biomedical sciences, WEE1, Drug development, Therapy, Ovarian cancer, Doctor of Philosophy, Eventide, Appointment, Cowen Inc.

NEW YORK and SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that Diana Hausman, M.D., a member of Zentalis’ Board of Directors, was appointed as Chief Medical Officer, and Kyle Rasbach, Ph.D., Pharm.D., was appointed as Chief Business Officer.

Key Points: 
  • “We are pleased to welcome Diana and Kyle to our management team.
  • During her career, she has contributed to the development of multiple cancer therapeutics, including small molecules, antibody drug conjugates, and immunotherapies.
  • In connection with her appointment as Chief Medical Officer, Dr. Hausman resigned from Zentalis’ Board of Directors.
  • Dr. Brownstein will remain with Zentalis as a consultant for a transitional period.

BMO 2024 ETF Industry Outlook: Structured Outcome ETFs expected to drive continued growth as investors seek innovative solutions

Retrieved on: 
Monday, January 22, 2024
ETF, Portfolio, Income tax, Magnificent, Bank of Canada, Microsoft, S&P Dow Jones Indices, Bank, Investment, NAV, Meta, Particular, Buffer, Prospectus, Bank of Montreal, Communication, Risk, Corporation, BMO, Dow Jones, Fed, S&P, The Magnificent Seven, CAD, Recession, ZWT, Portfolio manager, Growth

Structured Outcome ETFs provide an added level of transparency around investments and how they may perform going forward.

Key Points: 
  • Structured Outcome ETFs provide an added level of transparency around investments and how they may perform going forward.
  • To achieve the intended target outcomes sought by a Structured Outcome ETF for a Target Outcome Period, an investor must hold Units of the Structured Outcome ETF for that entire Target Outcome Period.
  • Commissions, management fees and expenses all may be associated with investments in BMO ETFs and ETF Series of the BMO Mutual Funds.
  • Please read the ETF facts or prospectus of the relevant BMO ETF or ETF Series before investing.

Jim Mooney Joins Autumn Lane as Partner and Chief Investment Officer

Retrieved on: 
Friday, January 19, 2024
Lehman Brothers, PwC, Partner, Texas A&M University, Knowledge, University, CIO, BBA, MBA, Alpha, Millennium Management, LLC, Portfolio manager

HOUSTON, Jan. 19, 2024 /PRNewswire/ -- Autumn Lane Advisors is delighted to announce the appointment of James "Jim" Mooney as a Partner and our Chief Investment Officer.

Key Points: 
  • HOUSTON, Jan. 19, 2024 /PRNewswire/ -- Autumn Lane Advisors is delighted to announce the appointment of James "Jim" Mooney as a Partner and our Chief Investment Officer.
  • Jim was involved in Autumn Lane's early history, not only contributing as member of our first Advisory Board but was also an early investor in the firm's investment partnerships.
  • With over 18 years of investment expertise, Jim assumes the role of CIO, further solidifying our commitment to delivering unparalleled investment knowledge.
  • Partner, David Andrew, expressed his enthusiasm, stating, "I've known Jim since our days in the investment banking group of Lehman Brothers over 20 years ago.